Adaptimmune Therapeutics plc (ADAP)
NASDAQ: ADAP · IEX Real-Time Price · USD
1.075
+0.015 (1.42%)
At close: Apr 26, 2024, 4:00 PM
1.090
+0.015 (1.40%)
After-hours: Apr 26, 2024, 7:36 PM EDT
Adaptimmune Therapeutics Revenue
In the year 2023, Adaptimmune Therapeutics had annual revenue of $60.28M with 122.05% growth. Revenue in the quarter ending December 31, 2023 was $231.00K, a -97.91% decrease year-over-year.
Revenue (ttm)
$60.28M
Revenue Growth
+122.05%
P/S Ratio
4.05
Revenue / Employee
$134,256
Employees
449
Market Cap
244.21M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 60.28M | 33.13M | 122.05% |
Dec 31, 2022 | 27.15M | 21.00M | 341.50% |
Dec 31, 2021 | 6.15M | 2.19M | 55.36% |
Dec 31, 2020 | 3.96M | 2.84M | 252.76% |
Dec 31, 2019 | 1.12M | -58.38M | -98.11% |
Dec 31, 2018 | 59.51M | 21.67M | 57.28% |
Dec 31, 2017 | 37.83M | 23.64M | 166.47% |
Dec 31, 2016 | 14.20M | 4.33M | 43.84% |
Jun 30, 2015 | 9.87M | 9.05M | 1,096.48% |
Jun 30, 2014 | 825.00K | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Bioventus | 512.35M |
Puma Biotechnology | 235.64M |
Agenus | 156.31M |
Nektar Therapeutics | 90.12M |
Utah Medical Products | 50.22M |
Fennec Pharmaceuticals | 21.25M |
ADAP News
- 15 days ago - Strategic Collaboration between Adaptimmune and Genentech to Research, Develop, and Commercialize Cancer-targeted Allogeneic T-cell Therapies Terminated - Newsfile Corp
- 4 weeks ago - Results of Adaptimmune's SPEARHEAD-1 Trial with Afami-cel in Advanced Sarcomas Published in the Lancet - Newsfile Corp
- 7 weeks ago - Adaptimmune Reports Q4/Full Year 2023 Financial Results and Business Updates - Newsfile Corp
- 2 months ago - Adaptimmune Hires Chief Commercial Officer in Advance of Q3 2024 PDUFA Date for Afami-cel, a Late-stage Product in the Company's Sarcoma Franchise - Newsfile Corp
- 2 months ago - Adaptimmune to Report Q4 and Full Year 2023 Financial and Business Updates on Wednesday, March 6, 2024 - Newsfile Corp
- 3 months ago - Adaptimmune Announces U.S. FDA Acceptance of Biologics License Application for Afami-cel for the Treatment of Advanced Synovial Sarcoma with Priority Review - Newsfile Corp
- 4 months ago - Adaptimmune Projects Sarcoma Franchise to Deliver US Peak Year Sales up to $400 Million - Presentation at JP Morgan Healthcare Conference - Newsfile Corp
- 5 months ago - Adaptimmune Completes Submission of Rolling Biologics License Application (BLA) to U.S. FDA for Afami-cel for the Treatment of Advanced Synovial Sarcoma - Newsfile Corp